Sandoz announced the creation of a standalone biosimilars division, appointing Armin Metzger to lead development, manufacturing and supply as the company positions to capture a wave of patent expiries worth hundreds of billions. The Swiss generics giant cited clear ownership and faster decision‑making as drivers for the split and said it expects biosimilars to benefit from an upcoming 'golden decade' of product off‑patent opportunities. Concurrently, U.S. FDA draft guidance signaled regulatory streamlining for biosimilars by reducing certain clinical pharmacokinetic testing burdens when comparators are approved outside the U.S. Together, the corporate reorganization and regulatory easing lower development friction for biosimilar sponsors, potentially accelerating market entry and competition across biologics. Sandoz emphasized retention of its low‑cost generics business while bolstering the distinct biosimilar operating model to scale biologic copycat programs. Named sources: Sandoz press release and U.S. FDA draft guidance on biosimilars. For context, biosimilar developers rely on both regulatory clarity and dedicated manufacturing scale to compete on cost and timely supply.